What Is an FDA Import Alert?

An FDA Import Alert is a border enforcement tool that allows FDA to detain imported shipments without physical examination when a product, manufacturer, or shipper presents a known compliance risk. Import Alerts are published on FDA's website and organized by country, product, and issue. They function as a standing instruction to FDA field staff: when a shipment matches an alert criteria, detention is automatic.

Import Alerts are not bans. A detained shipment may still enter if the importer demonstrates compliance, typically through laboratory testing, manufacturer certification, or other evidence. The burden shifts to the importer. For firms that advise on FDA import compliance, understanding the alert mechanism, the green list petition process, and the distinction between automatic detention and refusal is central to the work.

How Import Alerts Are Structured and Triggered

FDA maintains Import Alerts in a numbered series. Alert 99-35 covers products from firms that have refused FDA inspection under the Food Safety Modernization Act. Alert 16-129 lists firms with unresolved drug GMP issues. Alert 89-08 covers foods with repeated pesticide residue violations. Each alert specifies the scope, the evidence standard, and the detention instructions.

A shipment is subject to automatic detention when it matches all criteria in the alert. The criteria may include manufacturer name, product code, country of origin, or specific violation type. FDA's Operational and Administrative System for Import Support (OASIS) flags matching entries. The port of entry then issues a Notice of FDA Action, FDA Form 7666, stating the detention and the reason.

The Green List, Red List, and Black List

Import Alerts contain three categories of firms. The Green List names firms that have demonstrated compliance and are exempt from automatic detention for the specified alert. The Red List names specific firms, products, or shippers subject to detention. The Black List names firms that have requested but not completed a re-inspection, or that have withdrawn registration.

A firm on the Red List may petition for Green List status. The petition requires evidence that the violation has been corrected, often including third-party audit results, laboratory testing, and facility documentation. FDA reviews the petition, which may take months. There is no formal timeline for response. A denied petition may be resubmitted with additional evidence.

Why Import Alerts Matter to Compliance Firms

For an FDA import compliance practice, Import Alerts are both a risk indicator and a revenue signal. A client whose supplier appears on a Red List faces immediate supply chain disruption. The compliance firm must assess whether the detention is valid, whether the supplier can be moved to the Green List, or whether the client must source elsewhere.

The financial exposure can be substantial. A detained shipment incurs demurrage, storage fees, and potential spoilage for temperature-sensitive products. If the detention extends beyond the product's shelf life, the entire shipment is lost. For pharmaceutical ingredients, a detention may halt manufacturing and trigger contractual penalties with downstream customers.

Compliance firms also encounter Import Alerts in due diligence. A prospective client may not know that its foreign manufacturer is Red Listed. The alert may be the reason for a sudden quality complaint or a terminated supplier relationship. Identifying the alert early changes the engagement strategy from reactive remediation to proactive supply chain restructuring.

Common Errors in Import Alert Response

Practitioners and importers make specific, costly mistakes in handling Import Alerts.

Treating Detention as Refusal

A detained shipment is not refused. Refusal is a final decision after FDA review. Detention is a holding period, typically thirty days, during which the importer may submit evidence. Importers who treat detention as terminal often abandon shipments that could have been released. The compliance firm must clarify the timeline and the evidentiary options immediately.

Submitting Inadequate Green List Petitions

A Green List petition that merely states the firm has corrected the problem will fail. FDA requires documentary evidence: revised procedures, training records, verification testing, and often a third-party audit by an FDA-recognized body. Petitions that lack specific test methods, sampling plans, or chain-of-custody documentation are returned without review. The delay costs the importer ongoing detentions.

Failing to Monitor Alert Updates

Import Alerts are revised without direct notice to affected firms. A manufacturer may be added to the Red List based on a single adverse inspection at another facility under the same corporate registration. Importers who do not monitor alert revisions discover the problem only when a shipment is detained. Compliance firms should establish alert monitoring as a standard service component, not an ad hoc response.

Related Terms in Regulatory and Compliance

Practitioners in FDA import work should also understand FDA 483 Observation, the inspectional observation that often precedes Import Alert listing; FDA Warning Letter, the formal administrative step between 483 and enforcement; 510(k) Submission, the premarket notification for medical devices that may be subject to import review; FSMA, the statute that expanded FDA's authority to refuse entry based on inspection refusal; and ISO 13485, the quality management standard often cited in Green List petitions for medical device manufacturers.

If you operate an FDA import compliance firm, see how ROI Wire builds correspondence programs for regulatory compliance practices. For additional terms in this division, return to the Regulatory and Compliance glossary hub.